Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Unternehmen & Branche
| Name | OCULAR THERAPEUTIX, INC |
|---|---|
| Ticker | OCUL |
| CIK | 0001393434 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,03 Mrd. USD |
| Beta | 0,95 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 51,951,000 | -265,939,000 | -1.42 | 808,057,000 | 654,310,000 |
| 2025-09-30 | 10-Q | 14,544,000 | -69,418,000 | -0.38 | 410,882,000 | 258,229,000 |
| 2025-06-30 | 10-Q | 13,459,000 | -67,814,000 | -0.39 | 451,333,000 | 305,916,000 |
| 2025-03-31 | 10-Q | 10,698,000 | -64,053,000 | -0.38 | 405,920,000 | 265,930,000 |
| 2024-12-31 | 10-K | 63,723,000 | -193,506,000 | -1.22 | 457,935,000 | 315,344,000 |
| 2024-09-30 | 10-Q | 15,425,000 | -36,493,000 | -0.22 | 490,369,000 | 352,021,000 |
| 2024-06-30 | 10-Q | 16,441,000 | -43,777,000 | -0.26 | 517,091,000 | 377,695,000 |
| 2024-03-31 | 10-Q | 14,774,000 | -64,848,000 | -0.49 | 538,947,000 | 407,983,000 |
| 2023-12-31 | 10-K | 58,443,000 | -80,736,000 | -1.02 | 252,060,000 | 91,131,000 |
| 2023-09-30 | 10-Q | 15,081,000 | -516,000 | -0.25 | 162,384,000 | 7,853,000 |
| 2023-06-30 | 10-Q | 15,186,000 | -20,682,000 | -0.26 | 122,558,000 | 3,087,000 |
| 2023-03-31 | 10-Q | 13,374,000 | -30,318,000 | -0.39 | 128,573,000 | 9,711,000 |
| 2022-12-31 | 10-K | 51,494,000 | -71,038,000 | -0.97 | 149,289,000 | 35,379,000 |
| 2022-09-30 | 10-Q | 11,965,000 | -24,188,000 | -0.31 | 158,579,000 | 46,229,000 |
| 2022-06-30 | 10-Q | 12,266,000 | -18,766,000 | -0.25 | 173,071,000 | 65,803,000 |
| 2022-03-31 | 10-Q | 13,187,000 | -12,542,000 | -0.22 | 187,622,000 | 79,795,000 |
| 2021-12-31 | 10-K | 43,522,000 | -6,553,000 | -0.98 | 204,887,000 | 87,999,000 |
| 2021-09-30 | 10-Q | 12,153,000 | 2,657,000 | -0.23 | 217,739,000 | 87,340,000 |
| 2021-06-30 | 10-Q | 11,718,000 | -8,481,000 | -0.25 | 230,707,000 | 80,247,000 |
| 2021-03-31 | 10-Q | 7,342,000 | 3,121,000 | -0.24 | 243,040,000 | 83,408,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | Dugel Pravin | Director, Officer, See Remarks | Open Market Sale | -20,056 | 8.28 | -166,063.68 | -42,8% | |
| 2026-02-12 | Dugel Pravin | Director, Officer, See Remarks | Open Market Sale | -124,882 | 9.04 | -1,128,933.28 | -290,8% | |
| 2025-11-24 | Dugel Pravin | Director, Officer, See Remarks | Open Market Sale | -19,530 | 12.04 | -235,141.20 | -60,6% | |
| 2025-08-25 | Dugel Pravin | Director, Officer, See Remarks | Open Market Sale | -21,494 | 12.04 | -258,787.76 | -66,7% | |
| 2025-05-23 | Dugel Pravin | Director, Officer, See Remarks | Open Market Sale | -21,219 | 7.18 | -152,352.42 | -39,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.